- published: 09 Sep 2014
- views: 28
Create your page here
Thursday, 26 November 2015
back to playlist
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO | Mad Money | CNBC
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc...
- published: 17 Sep 2013
- views: 248
- author: kxan
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline?
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://cnb.cx/1RDkrfJ
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
- published: 13 Oct 2015
- views: 365
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev...
- published: 28 Sep 2011
- views: 416
- author: Cameron Bisset
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes...
- published: 12 Sep 2013
- views: 241
- author: TheStreet
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://www.cnbc.com/id/102623635
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
- published: 28 Apr 2015
- views: 249
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army.
SEE IT HERE: https://www.youtube.com/watch?v=rfI1W67YvaM
She knew that I was "in Andi's Army" and heard me talking to my wife and friends.
She wanted to help!
Since then she keeps asking if her video worked.... While the conversation about Compassionate Use has followed Andrea into the National Spotlight, #BioMarin has yet to grant Andrea access to the drug she needs. It BREAKS MY HEART to not be able to tell Audrey that her video message was actually heard by the people she hoped would listen.
I've been helping with Andi's Army. I love Andrea Sloan - She is a great role model for my daughters... but this video is meant to help support Audrey's "Fort Movie" - and inform as many as possible so that BioMarin will listen and take action to develop a meaningful compassionate use policy NOW- so I can tell Audrey her "movie" worked.
- published: 13 Sep 2013
- views: 117
Cramer Interviews BioMarin CEO.
- published: 21 Mar 2012
- views: 485
- author: TheStreet
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM...
- published: 22 Jul 2014
- views: 33
- author: Morquiosity
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h...
- published: 28 Sep 2012
- views: 164
- author: Kegottsleben
- Loading...
-
5:12BioMarin CEO | Mad Money | CNBC
BioMarin CEO | Mad Money | CNBCBioMarin CEO | Mad Money | CNBC
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC h -
4:44BioMarin explains reasoning in Sloan case
BioMarin explains reasoning in Sloan caseBioMarin explains reasoning in Sloan case
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc... -
6:14BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBCBioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about BioMarin here: http://cnb.cx/1RDkrfJ "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' -
8:58A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
A recipe for commercial success in orphan disease - Daniel Maher, BioMarinA recipe for commercial success in orphan disease - Daniel Maher, BioMarin
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev... -
2:02Biotech's Next Big Thing: BioMarin
Biotech's Next Big Thing: BioMarinBiotech's Next Big Thing: BioMarin
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes... -
5:55BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBCBioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about BioMarin here: http://www.cnbc.com/id/102623635 "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main -
3:07Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
Andrea Sloan's Story - Compassionate Use Denied by BioMarin PharmaceuticalAndrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army. SEE IT HERE: https://www.youtube.com/watch?v=rfI1W67YvaM She knew that I was "in Andi's Army" and heard me talking to my wife and friends. She wanted to help! Since then she keeps asking if her video worked.... While the conversation about Compassionate Use has followed Andrea into the National Spotlight, #BioMarin has yet to grant Andrea access to the drug she needs. It BREAKS MY HEART to not be able to tell Audrey that her video message was actually heard by the people she hoped would listen. I've been helping with Andi's Army. -
13:23BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
Speakers: Giles Campion, MD, PhD -
4:03Cramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEOCramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEO. -
18:14Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM... -
6:45BioMarin Talk
BioMarin TalkBioMarin Talk
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h... -
3:05BioMarin - Show Compassion to Andrea Sloan
BioMarin - Show Compassion to Andrea SloanBioMarin - Show Compassion to Andrea Sloan
Join us here: facebook.com/OfficialAndisArmy -
5:02(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc. -
6:48(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.
-
BioMarin CEO | Mad Money | CNBC
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle o -
BioMarin explains reasoning in Sloan case
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc... -
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about BioMarin here: http://cnb.cx/1RDkrfJ "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and succe -
A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev... -
Biotech's Next Big Thing: BioMarin
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes... -
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about BioMarin here: http://www.cnbc.com/id/102623635 "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful mo -
Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army. SEE IT HERE: https://www.youtube.com/watch?v=rfI1W67YvaM She knew that I was "in Andi's Army" and heard me talking to my wife and friends. She wanted to help! Since then she keeps asking if her video worked.... While the conversation about Compassionate Use has followed Andrea into the N -
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
Speakers: Giles Campion, MD, PhD -
Cramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEO. -
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM... -
BioMarin Talk
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h... -
BioMarin - Show Compassion to Andrea Sloan
Join us here: facebook.com/OfficialAndisArmy -
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc. -
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc. -
Fireside Chat With Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013 Jean-Jacques Bienaimé Chief Executive Offi... -
Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin Pharmaceutical Inc.
Jean-Jacques Bienaimé Chief Executive Officer, BioMarin Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of direct... -
Audrey Andis Army Soldier Fort Movie - "BioMarin Please Watch My Movie!!" - Audrey
UPDATE: Audrey asked me to make another movie. My daughter Audrey insisted on making this video for Andrea Sloan to share with the members of Andi's Army, a ... -
BioMarin R&D; Day - Technical Achon ppt - Dec 2011
Help support medical research. Visit http://www.growingstronger.org. Technical medical presentation about BioMarin's therapy for Achondroplasia. Public prese... -
Bio Marin's Celebration - Part 2
This is the second part of a photo essay on the documenting of a celebration of FDA's approval for a enzyme replacement therapy for the treatment of children. -
BioMarin Pharmaceutical (BMRN) Downgrade Alert, Watch for 8.4% Technical Uptrend Reversal
August 3, 2010 BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Hold from Buy at Roth Capital. The stock closed yesterday at $21.98 on volume of 1147200... -
Jean-Jacques & BioMarin - Andrea is not asking for "Special Treatment"
Jean-Jacques, CEO at BioMarin Pharmaceutical has continued to assert that Andrea Sloan is looking for special treatment, even resorting to name calling. Andi... -
News Update: BioMarin Pharmaceutical Inc. Purchases ZyStor Therapeutics in Deal as Much as $115M
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) officials announced that the company purchased privately-held biotechnology firm, ZyStor Therapeutics Inc., for up... -
Webinar: Selection and Deployment of the MODA-EM™ Solution for BioMarin Pharmaceutical
View the archived webinar and learn from the BioMarin Case Study how the MODA-EM™ Solution helps to successfully manage the specific needs of Environmental Monitoring (EM). To view the schedule of upcoming webinars, please visit www.lonza.com/qcwebinars.
BioMarin CEO | Mad Money | CNBC
- Order: Reorder
- Duration: 5:12
- Updated: 09 Sep 2014
- views: 28
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope.
» Subscribe to CNBC: http://cnb.cx/Subscrib...
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO | Mad Money | CNBC
wn.com/Biomarin Ceo | Mad Money | Cnbc
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer puts it under the microscope.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO | Mad Money | CNBC
- published: 09 Sep 2014
- views: 28
BioMarin explains reasoning in Sloan case
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc......
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc...
wn.com/Biomarin Explains Reasoning In Sloan Case
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why they have not granted Andrea Sloan access to the experimental canc...
- published: 17 Sep 2013
- views: 248
- author: kxan
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
- Order: Reorder
- Duration: 6:14
- Updated: 13 Oct 2015
- views: 365
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline?
» Subscribe...
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline?
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://cnb.cx/1RDkrfJ
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
wn.com/Biomarin Pharmaceutical Ceo Orphan Opportunity | Mad Money | Cnbc
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline?
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://cnb.cx/1RDkrfJ
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
- published: 13 Oct 2015
- views: 365
A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
- Order: Reorder
- Duration: 8:58
- Updated: 07 Apr 2014
- views: 416
- author: Cameron Bisset
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev......
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev...
wn.com/A Recipe For Commercial Success In Orphan Disease Daniel Maher, Biomarin
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial success in orphan disease • Understanding BioMarin's key drivers in dev...
- published: 28 Sep 2011
- views: 416
- author: Cameron Bisset
Biotech's Next Big Thing: BioMarin
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes......
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes...
wn.com/Biotech's Next Big Thing Biomarin
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet. http://www.thes...
- published: 12 Sep 2013
- views: 241
- author: TheStreet
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
- Order: Reorder
- Duration: 5:55
- Updated: 28 Apr 2015
- views: 249
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline.
» Subscribe to CNBC: http://cnb...
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://www.cnbc.com/id/102623635
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
wn.com/Biomarin Ceo Jean Jacques Bienaimé Pipeline Profits | Mad Money | Cnbc
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the biotech sector and powerful pipeline.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about BioMarin here: http://www.cnbc.com/id/102623635
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
- published: 28 Apr 2015
- views: 249
Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
- Order: Reorder
- Duration: 3:07
- Updated: 13 Sep 2013
- views: 117
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army.
SEE IT HERE: https://www.youtube.com/watch?v=rfI...
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army.
SEE IT HERE: https://www.youtube.com/watch?v=rfI1W67YvaM
She knew that I was "in Andi's Army" and heard me talking to my wife and friends.
She wanted to help!
Since then she keeps asking if her video worked.... While the conversation about Compassionate Use has followed Andrea into the National Spotlight, #BioMarin has yet to grant Andrea access to the drug she needs. It BREAKS MY HEART to not be able to tell Audrey that her video message was actually heard by the people she hoped would listen.
I've been helping with Andi's Army. I love Andrea Sloan - She is a great role model for my daughters... but this video is meant to help support Audrey's "Fort Movie" - and inform as many as possible so that BioMarin will listen and take action to develop a meaningful compassionate use policy NOW- so I can tell Audrey her "movie" worked.
wn.com/Andrea Sloan's Story Compassionate Use Denied By Biomarin Pharmaceutical
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted to join Andi's Army.
SEE IT HERE: https://www.youtube.com/watch?v=rfI1W67YvaM
She knew that I was "in Andi's Army" and heard me talking to my wife and friends.
She wanted to help!
Since then she keeps asking if her video worked.... While the conversation about Compassionate Use has followed Andrea into the National Spotlight, #BioMarin has yet to grant Andrea access to the drug she needs. It BREAKS MY HEART to not be able to tell Audrey that her video message was actually heard by the people she hoped would listen.
I've been helping with Andi's Army. I love Andrea Sloan - She is a great role model for my daughters... but this video is meant to help support Audrey's "Fort Movie" - and inform as many as possible so that BioMarin will listen and take action to develop a meaningful compassionate use policy NOW- so I can tell Audrey her "movie" worked.
- published: 13 Sep 2013
- views: 117
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
- Order: Reorder
- Duration: 13:23
- Updated: 17 Jul 2015
- views: 10
Speakers: Giles Campion, MD, PhD...
Speakers: Giles Campion, MD, PhD
wn.com/Biomarin (Drisapersen) Ppmd's 2015 Connect Confernece
Speakers: Giles Campion, MD, PhD
- published: 17 Jul 2015
- views: 10
Cramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEO....
Cramer Interviews BioMarin CEO.
wn.com/Cramer Interviews Biomarin Ceo
Cramer Interviews BioMarin CEO.
- published: 21 Mar 2012
- views: 485
- author: TheStreet
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
- Order: Reorder
- Duration: 18:14
- Updated: 28 Jul 2014
- views: 33
- author: Morquiosity
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM......
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM...
wn.com/Navigating The Healthcare System With Biomarin Patient And Physician Support (Bpps)
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). IMPORTANT SAFETY INFORM...
- published: 22 Jul 2014
- views: 33
- author: Morquiosity
BioMarin Talk
- Order: Reorder
- Duration: 6:45
- Updated: 07 Nov 2013
- views: 164
- author: Kegottsleben
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h......
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h...
wn.com/Biomarin Talk
This is a talk I did before my book signing at the headquarters of BioMarin In California. I had a wonderful time meeting everyone!! I appreciate all their h...
- published: 28 Sep 2012
- views: 164
- author: Kegottsleben
BioMarin - Show Compassion to Andrea Sloan
- Order: Reorder
- Duration: 3:05
- Updated: 19 Sep 2013
- views: 530
Join us here: facebook.com/OfficialAndisArmy...
Join us here: facebook.com/OfficialAndisArmy
wn.com/Biomarin Show Compassion To Andrea Sloan
Join us here: facebook.com/OfficialAndisArmy
- published: 19 Sep 2013
- views: 530
(BMRN) BioMarin Pharmaceutical, Inc.
- Order: Reorder
- Duration: 5:02
- Updated: 18 Jun 2015
- views: 11
(BMRN) BioMarin Pharmaceutical, Inc....
(BMRN) BioMarin Pharmaceutical, Inc.
wn.com/(Bmrn) Biomarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.
- published: 18 Jun 2015
- views: 11
(BMRN) BioMarin Pharmaceutical, Inc.
- Order: Reorder
- Duration: 6:48
- Updated: 25 Nov 2015
- views: 5
(BMRN) BioMarin Pharmaceutical, Inc....
(BMRN) BioMarin Pharmaceutical, Inc.
wn.com/(Bmrn) Biomarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.
- published: 25 Nov 2015
- views: 5
Fireside Chat With Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin
- Order: Reorder
- Duration: 31:53
- Updated: 06 Feb 2014
- views: 387
- author: Biotechnology Industry Organization
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013 Jean-Jacques Bienaimé Chief Executive Offi......
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013 Jean-Jacques Bienaimé Chief Executive Offi...
wn.com/Fireside Chat With Jean Jacques Bienaimé, Chief Executive Officer, Biomarin
From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013 Jean-Jacques Bienaimé Chief Executive Offi...
- published: 26 Feb 2013
- views: 387
- author: Biotechnology Industry Organization
Jean-Jacques Bienaimé, Chief Executive Officer, BioMarin Pharmaceutical Inc.
- Order: Reorder
- Duration: 0:54
- Updated: 06 Feb 2014
- views: 327
- author: Biotechnology Industry Organization
Jean-Jacques Bienaimé Chief Executive Officer, BioMarin Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of direct......
Jean-Jacques Bienaimé Chief Executive Officer, BioMarin Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of direct...
wn.com/Jean Jacques Bienaimé, Chief Executive Officer, Biomarin Pharmaceutical Inc.
Jean-Jacques Bienaimé Chief Executive Officer, BioMarin Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of direct...
- published: 26 Feb 2013
- views: 327
- author: Biotechnology Industry Organization
Audrey Andis Army Soldier Fort Movie - "BioMarin Please Watch My Movie!!" - Audrey
- Order: Reorder
- Duration: 1:05
- Updated: 29 Jul 2014
- views: 636
- author: Jim Walters IV
UPDATE: Audrey asked me to make another movie. My daughter Audrey insisted on making this video for Andrea Sloan to share with the members of Andi's Army, a ......
UPDATE: Audrey asked me to make another movie. My daughter Audrey insisted on making this video for Andrea Sloan to share with the members of Andi's Army, a ...
wn.com/Audrey Andis Army Soldier Fort Movie Biomarin Please Watch My Movie Audrey
UPDATE: Audrey asked me to make another movie. My daughter Audrey insisted on making this video for Andrea Sloan to share with the members of Andi's Army, a ...
- published: 09 Sep 2013
- views: 636
- author: Jim Walters IV
BioMarin R&D; Day - Technical Achon ppt - Dec 2011
- Order: Reorder
- Duration: 14:36
- Updated: 02 May 2013
- views: 930
- author: GrowingStrongerOrg
Help support medical research. Visit http://www.growingstronger.org. Technical medical presentation about BioMarin's therapy for Achondroplasia. Public prese......
Help support medical research. Visit http://www.growingstronger.org. Technical medical presentation about BioMarin's therapy for Achondroplasia. Public prese...
wn.com/Biomarin R D Day Technical Achon Ppt Dec 2011
Help support medical research. Visit http://www.growingstronger.org. Technical medical presentation about BioMarin's therapy for Achondroplasia. Public prese...
- published: 08 Jan 2012
- views: 930
- author: GrowingStrongerOrg
Bio Marin's Celebration - Part 2
This is the second part of a photo essay on the documenting of a celebration of FDA's approval for a enzyme replacement therapy for the treatment of children....
This is the second part of a photo essay on the documenting of a celebration of FDA's approval for a enzyme replacement therapy for the treatment of children.
wn.com/Bio Marin's Celebration Part 2
This is the second part of a photo essay on the documenting of a celebration of FDA's approval for a enzyme replacement therapy for the treatment of children.
- published: 13 Sep 2007
- views: 235
- author: Color3Lab
BioMarin Pharmaceutical (BMRN) Downgrade Alert, Watch for 8.4% Technical Uptrend Reversal
- Order: Reorder
- Duration: 0:51
- Updated: 26 Nov 2013
- views: 154
- author: TradeTheTrend
August 3, 2010 BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Hold from Buy at Roth Capital. The stock closed yesterday at $21.98 on volume of 1147200......
August 3, 2010 BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Hold from Buy at Roth Capital. The stock closed yesterday at $21.98 on volume of 1147200...
wn.com/Biomarin Pharmaceutical (Bmrn) Downgrade Alert, Watch For 8.4 Technical Uptrend Reversal
August 3, 2010 BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Hold from Buy at Roth Capital. The stock closed yesterday at $21.98 on volume of 1147200...
- published: 03 Aug 2010
- views: 154
- author: TradeTheTrend
Jean-Jacques & BioMarin - Andrea is not asking for "Special Treatment"
- Order: Reorder
- Duration: 1:17
- Updated: 08 Jan 2014
- views: 139
- author: Andis Army
Jean-Jacques, CEO at BioMarin Pharmaceutical has continued to assert that Andrea Sloan is looking for special treatment, even resorting to name calling. Andi......
Jean-Jacques, CEO at BioMarin Pharmaceutical has continued to assert that Andrea Sloan is looking for special treatment, even resorting to name calling. Andi...
wn.com/Jean Jacques Biomarin Andrea Is Not Asking For Special Treatment
Jean-Jacques, CEO at BioMarin Pharmaceutical has continued to assert that Andrea Sloan is looking for special treatment, even resorting to name calling. Andi...
- published: 23 Sep 2013
- views: 139
- author: Andis Army
News Update: BioMarin Pharmaceutical Inc. Purchases ZyStor Therapeutics in Deal as Much as $115M
- Order: Reorder
- Duration: 0:45
- Updated: 24 Nov 2013
- views: 231
- author: TradeTheTrend
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) officials announced that the company purchased privately-held biotechnology firm, ZyStor Therapeutics Inc., for up......
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) officials announced that the company purchased privately-held biotechnology firm, ZyStor Therapeutics Inc., for up...
wn.com/News Update Biomarin Pharmaceutical Inc. Purchases Zystor Therapeutics In Deal As Much As 115M
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) officials announced that the company purchased privately-held biotechnology firm, ZyStor Therapeutics Inc., for up...
- published: 18 Aug 2010
- views: 231
- author: TradeTheTrend
Webinar: Selection and Deployment of the MODA-EM™ Solution for BioMarin Pharmaceutical
- Order: Reorder
- Duration: 39:29
- Updated: 19 Nov 2014
- views: 15
View the archived webinar and learn from the BioMarin Case Study how the MODA-EM™ Solution helps to successfully manage the specific needs of Environmental Moni...
View the archived webinar and learn from the BioMarin Case Study how the MODA-EM™ Solution helps to successfully manage the specific needs of Environmental Monitoring (EM).
To view the schedule of upcoming webinars, please visit www.lonza.com/qcwebinars.
wn.com/Webinar Selection And Deployment Of The Moda Em™ Solution For Biomarin Pharmaceutical
View the archived webinar and learn from the BioMarin Case Study how the MODA-EM™ Solution helps to successfully manage the specific needs of Environmental Monitoring (EM).
To view the schedule of upcoming webinars, please visit www.lonza.com/qcwebinars.
- published: 19 Nov 2014
- views: 15
close fullscreen
fullscreen slideshow
- Playlist
- Chat
close fullscreen
fullscreen slideshow
- Playlist
- Chat
5:12
BioMarin CEO | Mad Money | CNBC
BioMarin Pharmaceutical is leading the fight against rare genetic diseases. Jim Cramer put...
published: 09 Sep 2014
BioMarin CEO | Mad Money | CNBC
BioMarin CEO | Mad Money | CNBC
- published: 09 Sep 2014
- views: 28
4:44
BioMarin explains reasoning in Sloan case
Top executives of the drug-making company, BioMarin, explained to shareholders Tuesday why...
published: 17 Sep 2013
author: kxan
BioMarin explains reasoning in Sloan case
BioMarin explains reasoning in Sloan case
- published: 17 Sep 2013
- views: 248
-
author:
kxan
Add Playlist for this Author
6:14
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Sho...
published: 13 Oct 2015
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
- published: 13 Oct 2015
- views: 365
8:58
A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
http://www.terrapinn.com/2012/world-orphan-drug-congress-usa/ A recipe for commercial succ...
published: 28 Sep 2011
author: Cameron Bisset
A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
A recipe for commercial success in orphan disease - Daniel Maher, BioMarin
- published: 28 Sep 2011
- views: 416
-
author:
Cameron Bisset
Add Playlist for this Author
2:02
Biotech's Next Big Thing: BioMarin
BioMarin's R&D; update next Tuesday will be the biggest thing in biotech in the coming week...
published: 12 Sep 2013
author: TheStreet
Biotech's Next Big Thing: BioMarin
Biotech's Next Big Thing: BioMarin
- published: 12 Sep 2013
- views: 241
-
author:
TheStreet
Add Playlist for this Author
5:55
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
Jim Cramer’s interview with the CEO of orphan drug maker BioMarin, on its strength in the ...
published: 28 Apr 2015
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profits?| Mad Money | CNBC
- published: 28 Apr 2015
- views: 249
3:07
Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
Last weekend, my daughter asked to make a video for Andrea Sloan (Andi) because she wanted...
published: 13 Sep 2013
Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
Andrea Sloan's Story - Compassionate Use Denied by BioMarin Pharmaceutical
- published: 13 Sep 2013
- views: 117
13:23
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
Speakers: Giles Campion, MD, PhD...
published: 17 Jul 2015
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]
- published: 17 Jul 2015
- views: 10
4:03
Cramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEO....
published: 21 Mar 2012
author: TheStreet
Cramer Interviews BioMarin CEO
Cramer Interviews BioMarin CEO
- published: 21 Mar 2012
- views: 485
-
author:
TheStreet
Add Playlist for this Author
18:14
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
INDICATION VIMIZIM(TM) (elosulfase alfa) is indicated for patients with Mucopolysaccharido...
published: 22 Jul 2014
author: Morquiosity
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
Navigating the healthcare system with BioMarin Patient and Physician Support (BPPS)
- published: 22 Jul 2014
- views: 33
-
author:
Morquiosity
Add Playlist for this Author
6:45
BioMarin Talk
This is a talk I did before my book signing at the headquarters of BioMarin In California....
published: 28 Sep 2012
author: Kegottsleben
BioMarin Talk
BioMarin Talk
- published: 28 Sep 2012
- views: 164
-
author:
Kegottsleben
Add Playlist for this Author
3:05
BioMarin - Show Compassion to Andrea Sloan
Join us here: facebook.com/OfficialAndisArmy...
published: 19 Sep 2013
BioMarin - Show Compassion to Andrea Sloan
BioMarin - Show Compassion to Andrea Sloan
- published: 19 Sep 2013
- views: 530
5:02
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc....
published: 18 Jun 2015
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.
- published: 18 Jun 2015
- views: 11
6:48
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc....
published: 25 Nov 2015
(BMRN) BioMarin Pharmaceutical, Inc.
(BMRN) BioMarin Pharmaceutical, Inc.
- published: 25 Nov 2015
- views: 5
BioMarin CEO | Mad Money | CNBC...
BioMarin explains reasoning in Sloan case...
BioMarin Pharmaceutical CEO: Orphan Opportunity? ...
A recipe for commercial success in orphan disease ...
Biotech's Next Big Thing: BioMarin...
BioMarin CEO Jean-Jacques Bienaimé: Pipeline Profi...
Andrea Sloan's Story - Compassionate Use Denied by...
![BioMarin (Drisapersen) [PPMD's 2015 Connect Confernece]](http://web.archive.org./web/20151126202535/http://i.ytimg.com/vi/2MZFs6fTTNw/0.jpg)
BioMarin (Drisapersen) [PPMD's 2015 Connect Confer...
Cramer Interviews BioMarin CEO...
Navigating the healthcare system with BioMarin Pat...
BioMarin Talk...
BioMarin - Show Compassion to Andrea Sloan...
(BMRN) BioMarin Pharmaceutical, Inc....
(BMRN) BioMarin Pharmaceutical, Inc....
Fireside Chat With Jean-Jacques Bienaimé, Chief Ex...
Jean-Jacques Bienaimé, Chief Executive Officer, Bi...
Audrey Andis Army Soldier Fort Movie - "BioMarin P...
BioMarin R&D; Day - Technical Achon ppt - Dec 2011...
Bio Marin's Celebration - Part 2...
BioMarin Pharmaceutical (BMRN) Downgrade Alert, Wa...
Jean-Jacques & BioMarin - Andrea is not asking for...
News Update: BioMarin Pharmaceutical Inc. Purchas...
Webinar: Selection and Deployment of the MODA-EM™ ...
photo: AP / Kayhan Ozer, Presidential Press Service, Pool
Russia to impose economic sanctions on Turkey over jet downing
Edit Belfast Telegraph 26 Nov 2015
Russia plans to retaliate against Turkey following the downing of a warplane by imposing sanctions, cutting economic ties and scrapping major investment projects. Since the plane was shot down in disputed circumstances on the Syria-Turkey border on Tuesday, Russia has already restricted tourism, left Turkish trucks stranded at the border and announced the confiscation of large quantities of Turkish food imports. Share Go To ... He said ... ....
photo: AP / Jose Luis Magana
Donald Trump criticised after mocking reporter’s disability
Edit The Irish Times 26 Nov 2015
Donald Trump has been criticised after apparently mimicking a New York Times reporter’s physical disability. Speaking at a rally in South Carolina on Tuesday, the Republican US presidential candidate mocked Serge Kovaleski, a reporter who has contested Mr Trump’s claims that thousands of people celebrated in New Jersey after the 9/11 attacks ... He said ... Much of that has, indeed, faded from memory ... “Now the poor guy ... ‘I don’t remember....
photo: AP / Jordan Strauss/Invision
Mafia Heir Warns ISIS That New York Is Off Limits And Asks Robert De Niro ...
Edit Inquisitr 25 Nov 2015
The son of a New York mobster has warned ISIS to stay the hell out of the Big Apple and believes “Hollywood gangsters” such as Robert De Niro and Al Pacino need to step up to the plate and publicly make a stand against ISIS. Giovanni Gambino, whose father is a key figure in the... ....
photo: AP / Chicago Police Department via AP
Chicago officer had history of complaints before Laquan McDonald shooting
Edit CNN 26 Nov 2015
(CNN)Jason Van Dyke, the Chicago police officer charged in Laquan McDonald's shooting death, had a history of complaints before he gunned down the 17-year-old last year -- and in almost every case, he was cleared in one way or another. The allegations mostly involve excessive force, and at least one complaint alleges he used a racial slur ... What's known is he has two children -- 9 and 14 -- and a wife, Tiffany ... Read More ... JUST WATCHED ... ......
photo: NASA / Greg Shirah
"Mouse" Spotted On Mars
Edit IFL Science 25 Nov 2015
First there were the "Clangers," then there were the "Biker Mice From Mars." Now, an amateur astronomer believes he may have spotted evidence of a real-life rodent race on the Red Planet, after trawling through images captured by NASA’s Curiosity rover ... Curiosity captured the image during its 509th Mars day, also known as a sol ... ....
« back to news headlines
Our Coverage Universe Sorted By Company Name (Valuentum Securities Inc)
Edit Public Technologies 26 Nov 2015
(Source. Valuentum Securities Inc). View Newsletter Archive -- view our actively-managed portfolios. Please find a list of our coverage universe of 16-page equity reports below. The companies are sorted by 'company name.' To access the report of your choosing, please use the 'Symbol' search box in our website header ... FAQ >>Testimonials >> Company Name Symbol Sector Industry ... BioMarin Pharma BMRN Health Care Biotechnology ... C. R ... D....
Our Coverage Universe Sorted By Ticker Symbol (Valuentum Securities Inc)
Edit Public Technologies 26 Nov 2015
(Source. Valuentum Securities Inc). View Newsletter Archive -- view our actively-managed portfolios. Please find a list of our coverage universe of 16-page equity reports below. The companies are sorted by 'ticker symbol.' To access the report of your choosing, please use the 'Symbol' search box in our website header ... FAQ >>Testimonials >> Symbol Company Name Sector Industry ... R ... BMRN BioMarin Pharma Health Care Biotechnology ... R....
FDA Advisory Committee Discusses Clinical Data Package for BioMarin's Kyndrisa(TM) (drisapersen) for the Treatment of ...
Edit Stockhouse 25 Nov 2015
24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc ... "I’d like to thank the patients, families and physicians who participated in Kyndrisa clinical trials and in today’s panel discussion,” said Jean-Jacques Bienaimé, chairman and chief executive officer of BioMarin. “We look forward to continuing our efforts to bring Kyndrisa to the Duchenne community ... About BioMarin....
BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel
Edit Yahoo Daily News 25 Nov 2015
BioMarin Pharmaceutical Inc. BMRN announced that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee’s vote on Kyndrisa was not favorable ... The FDA is expected to render a final decision on the candidate by Dec 27, 2015 ... Only one panelist voted that the discussions on Study 1 and Study 2 strengthened Biomarin’s case ... BioMarin carries a Zacks Rank #3 (Hold) ... . BIOMARIN PHARMA (BMRN) ... ... ....
Why this company's $700 million bet could come up short
Edit Business Journal 25 Nov 2015
A risky bet by BioMarin Pharmaceutical Inc. may come up with little to nothing to show for a North Bay rare disease drug development company. A Food and Drug Administration advisory panel Tuesday recommended that the agency not approve BioMarin's experimental treatment for an inherited muscle-wasting disease, called Duchenne muscular dystrophy. The recommendation could open the door for competitor Sarepta Therapeutics (NASDAQ ... ....
FDA panel: BioMarin muscle wastage drug data not persuasive
Edit Yahoo Daily News 25 Nov 2015
Food and Drug Administration on Tuesday indicated that efficacy data submitted by BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle ......
UPDATE 2-FDA panel says BioMarin DMD drug data not persuasive enough
Edit Reuters 25 Nov 2015
Nov 24 (Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration indicated that efficacy data from BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive enough to warrant approval. ....
Here’s what former Sarepta CEO Chris Garabedian had to say about BioMarin’s drug panel
Edit Business Journal 25 Nov 2015
Watching an FDA advisory committee tear apart the data his former competitor submitted seeking approval of its potential drug for Duchenne muscular dystrophy, Chris Garabedian felt some amount of vindication. The former CEO of Sarepta Therapeutics (Nasdaq. SRPT), who stepped down in March as the company faced mounting hurdles, watched via webcast as the federal agency debunked several claims made by BioMarin Pharmaceuticals (Nasdaq ... ......
Fatal Disease Drug in Limbo
Edit The Scientist 25 Nov 2015
An advisory panel to the US Food and Drug Administration (FDA) convened Tuesday (November 24) to evaluate the strength of evidence for drisapersen, a drug for the often fatal muscle disease Duchenne muscular dystrophy (DMD). Drisapersen, produced by BioMarin Pharmaceutical , has been tested in three placebo-controlled clinical trials, but the panel concluded none had shown clear evidence that the drug was helping ... ....
BioMarin Posts Presentation From FDA Advisory Committee Meeting for Kyndrisa(TM) (drisapersen) for the Treatment of ...
Edit Stockhouse 24 Nov 2015
24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc ... Interested parties may access BioMarin’s presentation from today’s Advisory Committee meeting via the link below to the investor section of the BioMarin website ... About BioMarin. BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases....
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Announced Today the Stock is Halted
Edit Stockhouse 24 Nov 2015
24, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc ... Food and Drug Administration (FDA) is meeting today to review BioMarin’s New Drug Application (NDA) for Kyndrisa, an investigational antisense oligonucleotide drug candidate for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping ... About BioMarin ... Investors Traci McCarty BioMarin Pharmaceutical Inc....
- 1
- 2
- 3
- 4
- 5
- Next page »
